Skip to content

LIVE WEBINAR

Applying Adimab's Diverse Tools for Novel T Cell Engagers

See how Adimab's proprietary T cell binders and heterodimerization solutions accelerate the design and development of multispecific T cell engagers.

December 3, 2026

2:00 pm ET

Online • Free to attend

About the webinar

Currently approved monospecific antibodies are often not effective enough for every patient or indication. As a result, the immunotherapy field is expanding toward molecules that engage multiple signaling pathways and cell types at once.

Adimab's proprietary αCD3, αCD28, and αTCR binders, combined with our novel heterodimerization solutions, enable partners to accelerate the design and development of T cell engagers (TCEs).

In this webinar, William Roach will demonstrate these capabilities through multispecifics that leverage Adimab's optimized T cell engager antibody panels.

What you'll learn

Why immunotherapy is moving beyond monospecific antibodies
How Adimab's αCD3, αCD28, and αTCR binders support TCE design
How heterodimerization solutions enable bispecific and higher-order formats
Examples of multispecifics built on optimized TCE panels

PRESENTER

William R

 

William Roach, PhD

Senior Director, Technology Alliances | Adimab

William earned his PhD in Cell and Molecular Biology from Washington University in St. Louis and completed postdoctoral training in Biochemistry at Dartmouth College. He then joined Adimab in 2008 in antibody engineering, focusing on building the platform and executing discovery and engineering programs. He subsequently moved into the Strategic Alliances and Business Development group and focuses on establishing new partnerships and strategically monitoring the biologics landscape. 

Register for the webinar

Join us live on December 3, 2026 at 2 pm ET. This webinar will not be recorded, so do not miss your chance to hear William speak.

About Adimab

Adimab is the most successful antibody discovery and engineering company in the industry and the partner of choice for biopharma. Since 2007, we’ve collaborated with more than 140 partners in global pharma, cutting-edge biotech, and leading academic institutions to generate high-quality therapeutic leads across a wide range of targets and formats. Together, we’ve completed more than 675 discovery campaigns, yielding over 90 clinical programs and six commercial products.

Our proprietary yeast-based platform enables end-to-end discovery, optimization, and developability assessment, reliably and efficiently delivering fully human IgGs, HCAbs, multispecifics, and other protein-based modalities, including TCRs.

Questions about partnering? Contact our business development team at bd@adimab.com.